A. Jaén-Morago

Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer

Alfonso Sánchez‐Muñoz, A. García-Tapiador, Esther Martínez-Ortega et al. · Clinical & Translational Oncology · 2008 · 57 citations

Advanced Breast Cancer, Breast Oncology, Medicine +9

The Role of Immunohistochemistry in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: An Old Tool With an Enduring Prognostic Value

Alfonso Sánchez‐Muñoz, Yéssica Plata-Fernández, Margarita Fernández et al. · Clinical Breast Cancer · 2013 · 39 citations

Breast Oncology, Breast Cancer Patients, Medicine +10

Is it Possible to Increase pCR in the Neoadjuvant Treatment With a Dose-Dense/Sequential Combination?

Alfonso Sánchez‐Muñoz, R. Dueñas-García, A. Jaén-Morago et al. · American Journal of Clinical Oncology · 2010 · 14 citations

Tumor histological subtyping determined by hormone receptors and HER2 status defines different pathological complete response and outcome to dose-dense neoadjuvant chemotherapy in breast cancer patients

Alfonso Sánchez‐Muñoz, Yéssica Plata-Fernández, A. Jaén-Morago et al. · Clinical & Translational Oncology · 2013 · 13 citations

Breast Oncology, Medicine, Gynecology +9